Discloses the use of an immunotherapeutic composition comrpising a yeast vehicle, a Brachyury antigen and a further agent selected from the group consisting of an immunotherapeutic virus-based vaccine, a cytokine, a T-cell co-stimulator, a immunomodulator, CD40, anti-CTLA-4 antibody, anti-PD-1, anti-PD-L1, anti-PD-L2 in the manufacture of a medicament for treating cancer. Further discloses a recombinant nucleic acid molecule encoding a fusion protein comprising at least one Brachyury antigen.